logo
logo
AI + EXCLUSIVE DATA

AI analyzes funding data you can't access anywhere else

Our proprietary AI monitors 15,000+ companies and identifies which funded companies need YOUR specific solution right now.

10-25 personalized leads daily • 92% average intent score • Smart feed technology
Start with:
Flexible Plans • $39/mo or $29/mo annual
AI + real-time funding intelligence
Never see duplicates in your feed
INDUSTRY FIRST

Synaptogenix, Inc. announced it raised $12.5 Million in an initial filing from an offering of $12.5 Million

Jun 29, 2021about 4 years ago

Amount Raised

$12.5 Million

New YorkTherapeuticsHealth CareBiotechnology

Company Information

Company

Synaptogenix

Location

1185 AVENUE OF THE AMERICAS

New York, New York, United States

About

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.

FundzWatch™ Score

87
Medium Activity

Related People

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech